Liposomal curcumin with radiation and temozolomide for new brain cancer
Part of Cancer clinical trials.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have a confirmed high-grade brain tumor (WHO grade III or IV), including certain specific subtypes
- Your standard treatment plan must be radiation (XRT) plus temozolomide (TMZ) for 6 weeks, then TMZ for six 28-day cycles
- Your general strength level must be adequate (Karnofsky score of 70 or higher)
- Blood counts and organ function must meet lab thresholds (enough red cells, white cells, platelets, and liver/kidney results)
- You must not be pregnant or breastfeeding, and you must use birth control if you can get pregnant or make someone pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a short course of chemotherapy (temozolomide) given before radiation can improve outcomes for people with newly diagnosed high-grade gliomas. It is designed for patients who are stable enough to delay starting radiation by a few weeks.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This study compares a standard radiation schedule versus a shorter, higher-dose radiation schedule, both with the chemotherapy medicine temozolomide, in older adults with newly diagnosed glioblastoma. It aims to see which approach works better and is practical for people age 70 and older.
This trial tests a daily chemo drug (temozolomide) in patients aged 65 or older with a specific type of aggressive brain cancer that has a certain genetic marker. It aims to see if this daily schedule works well after initial radiation and chemo.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.